chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Ear pain; Sore arm; Rash; Woke up last night all wet; Had a lot of gas in chest; Fever; Runny nose; If burped, felt better; Asthma; a lot of coughing; This spontaneous case was reported by a consumer and describes the occurrence of RHINORRHOEA (Runny nose), ERUCTATION (If burped, felt better), ASTHMA (Asthma), COUGH (a lot of coughing) and HYPERHIDROSIS (Woke up last night all wet) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039K20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Asthma and Splenectomy. Concurrent medical conditions included Seasonal allergy, Allergy (Smoke), Drug allergy (Allergy to Bactrim), Drug allergy (ciprofloxacin) and Sleep apnea. Concomitant products included FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE (ADVAIR) for Asthma.   On 09-Feb-2021 at 11:15 AM, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Feb-2021, the patient experienced RHINORRHOEA (Runny nose), ERUCTATION (If burped, felt better), ASTHMA (Asthma), COUGH (a lot of coughing) and PYREXIA (Fever). On 10-Feb-2021, the patient experienced HYPERHIDROSIS (Woke up last night all wet) and FLATULENCE (Had a lot of gas in chest). On 11-Feb-2021, the patient experienced RASH (Rash). On an unknown date, the patient experienced EAR PAIN (Ear pain) and PAIN IN EXTREMITY (Sore arm). The patient was treated with AZATADINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE (CORICIDIN DM) at an unspecified dose and frequency; IBUPROFEN (ADVIL 12 HOUR) at an unspecified dose and frequency and FLUTICASONE PROPIONATE (FLONASE ALLERGY RELIEF) at an unspecified dose and frequency. At the time of the report, RHINORRHOEA (Runny nose), ERUCTATION (If burped, felt better), ASTHMA (Asthma), COUGH (a lot of coughing), HYPERHIDROSIS (Woke up last night all wet), FLATULENCE (Had a lot of gas in chest), EAR PAIN (Ear pain), RASH (Rash) and PYREXIA (Fever) outcome was unknown and PAIN IN EXTREMITY (Sore arm) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 10-Feb-2021, Oxygen saturation: 98 (normal) Normal.         Most recent FOLLOW-UP information incorporated above includes: On 12-Feb-2021: Additional information received
Facial numbness middle to left side of chin and over to check, including lower lip and tip of tongue. First spoke with dentist and he took xrays to see if there was anything related he did not see anything, suggested I see my doctor. Had appt. with my family doctor and she did bloodwork, only issue with bloodwork was very low B12, began a daily supplement. Family suggested I see a neurologist to figure out this numbness. Went to neurologist, had more bloodwork and an MRI.. MRI was negative and bloodwork showed low albumin. I did document this on my weekly check-in post vaccine and in May received a call from CDC to report this adverse event. I had not correlated this to the vaccine, but once the CDC called, I did investigate and it seems that this could very well be a side effect. I am hoping someone can help me find a doctor that can help correct this numbness, thank you~
This spontaneous report as received from a registered nurse refers to a patient of unknown age and gender. The patient's medical history and concurrent conditions were not reported. On an unknown date, the patient received GARDASIL for her first dose and GARDASIL 9 as a second dose. No adverse symptoms reported. The outcome of the events was unknown. Additional information has been requested.
Patient reported knot in her arm where vaccine was administered and that she couldn't raise her arm above her head. Patient stated she needed help the next day getting dressed.
swelling and tenderness at the site of the injection; swelling and tenderness at the site of the injection; This is a spontaneous report received from a contactable reporter(s) (Other HCP).  An infant patient received pneumococcal 13-val conj vac (dipht crm197 protein) (PREVNAR 13) (Batch/Lot number: unknown) as dose 1, single. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: VACCINATION SITE SWELLING (non-serious), VACCINATION SITE PAIN (non-serious), outcome "unknown" and all described as "swelling and tenderness at the site of the injection". No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.  Additional information: Event took place after use of product.
Patient presented to pharmacy to received covid-19 vaccine after her doctor asked her to received vaccine due to HTN, DM chronic diseases. Patient received vaccine around 1:05pm and proceed to waiting area within less than 5 minutes patient started to feel sick and experienced nausea, cold sweats, and palpitations. Assisted patient taking BP, 1st reading 195/72 HR:124, 2nd reading 106/67 HR 96. EMS arrived to pharmacy and patient was taken to hospital.
Information has been received from a physician concerning an 18 year old female who on 13-OCT-2010 was vaccinated SC with the first 0.5ml dose of GARDASIL (Lot# 0938AA/1354AA, exp date 26-JUN-2014) and on an unspecified date was vaccinated with the second dose of GARDASIL (Lot# and route not reported). On 15-NOV-2011 the patient experienced weakness in her body and lower extremities, nausea, headaches, vomiting and an altered mental status after receiving a second injection on GARDASIL. The patient was hospitalized in the ER at an unspecified location for an unspecified duration of time. MORPHINA (strength and manufacturer unspecified) was given for her headaches. The doses of GARDASIL were also given outside the recommended dosing schedule for this product. The patient did many unspecified tests. At the time of the report, the patient was not recovered from the events. Additional information has been requested.
Rash/systemic body rash; Small, fainted redness; circle-shaped in shoulder were dose was infected; chills; Body aches; Fever; Unbelievable welts/welts that look like veins or lines all over back from shoulders to waist. It is constant,; Skin is hot; Itching; Hotness; Flu-like symptoms; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (Unbelievable welts/welts that look like veins or lines all over back from shoulders to waist. It is constant,), SKIN WARM (Skin is hot), PRURITUS (Itching), FEELING HOT (Hotness) and INFLUENZA LIKE ILLNESS (Flu-like symptoms) in a 22-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 030H21B, 006B21A and 025B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 25-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 02-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. In December 2021, the patient experienced URTICARIA (Unbelievable welts/welts that look like veins or lines all over back from shoulders to waist. It is constant,), SKIN WARM (Skin is hot), PRURITUS (Itching), FEELING HOT (Hotness), INFLUENZA LIKE ILLNESS (Flu-like symptoms), VACCINATION SITE ERYTHEMA (Small, fainted redness; circle-shaped in shoulder were dose was infected), CHILLS (chills), MYALGIA (Body aches) and PYREXIA (Fever). On 16-Dec-2021, the patient experienced RASH (Rash/systemic body rash). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency and CETIRIZINE HYDROCHLORIDE (ZYRTEC ALLERGY) at an unspecified dose and frequency. In December 2021, INFLUENZA LIKE ILLNESS (Flu-like symptoms), CHILLS (chills), MYALGIA (Body aches) and PYREXIA (Fever) had resolved. At the time of the report, URTICARIA (Unbelievable welts/welts that look like veins or lines all over back from shoulders to waist. It is constant,) and RASH (Rash/systemic body rash) had not resolved and SKIN WARM (Skin is hot), PRURITUS (Itching), FEELING HOT (Hotness) and VACCINATION SITE ERYTHEMA (Small, fainted redness; circle-shaped in shoulder were dose was infected) outcome was unknown.            No concomitant medication reported Patient was given a steroid shot and steroid pills (to decrease quantity gradually) in ER It was reported that symptoms stated on 16-Dec-2021 and patient went to ER on 18-Dec-2021 for rash. It was reported that patient was still the same. Had no improved from the rash.   This case was linked to MOD-2021-436372, MOD-2021-436309 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 31-Dec-2021: Follow up received included non significant information.; Sender's Comments:  MOD-2021-436372:Dose 2 MOD-2021-436309:Dose 1
The expiration date of this unopened vial was 06/01/2023, however, the Beyond Use Date in the refrigerator was 11/19/22. The vaccine was given 48 hours after the Beyond Use Date.  I contacted the manufacturer and obtained information that states "The vaccine administered on November 21, 2022 from lot number 021H22A maintained the activity necessary to protect against the SARS-CoV-2 (COVID-19) virus at the time of administration".  However, they cannot guarantee vaccine given after the 30 day BUD received protection similar to what was seen in clinical trials. I contacted the patient after I obtained information from the manufacturer and informed her to call me if she has an adverse reaction that she believes can be attributed to the COVID vaccine. NO ADVERSE EVENT WAS REPORTED BY PATIENT AT THIS TIME.
reconstituted with other diluent (MMR) and injected; reconstituted with other diluent (MMR) and injected; This case was reported by a other health professional via call center representative and described the occurrence of inappropriate reconstitution technique in a patient who received Herpes zoster (Shingrix) (batch number A4354, expiry date 30th March 2023) for prophylaxis.   On 8th November 2021, the patient received Shingrix (intramuscular). On an unknown date, unknown after receiving Shingrix, the patient experienced inappropriate reconstitution technique and inappropriate reconstitution technique. On an unknown date, the outcome of the inappropriate reconstitution technique and inappropriate reconstitution technique were unknown.  Additional details were reported as follows: The age at vaccination was not reported The patient received a dose of Shingrix which constituted other diluent (one with MMR), which led to inappropriate reconstitution technique and inappropriate reconstitution technique.
very high pitched-cry staring episodes-onset 2hr p/vax;t101 maximum;episode duration approx 3hr;no recurrence
Severe pain and swelling at vaccine site x12 days. Pain was not relieved with Aleve. Pain keep me up at night. Severe headache that has not gone away since vaccine. Nausea and vomiting x seven days. Tightness in chest  Heart palpitations
GAINED 9KG (ABOUT 18 POUNDS. EVERY DAY SHE GETS ON THE SCALE AND SHE SEES 2.2 KG MORE NON STOP. IT INCREASES EVERY DAY); WHOLE BODY SWOLLEN; This spontaneous report received from a patient concerned a 37 year old female. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unk) dose was not reported, administered on 09-SEP-2021 12:30 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On SEP-2021, Laboratory data included: Lab test (NR: not provided) numbers are good. On 10-SEP-2021, the patient experienced gained 9kg (about 18 pounds. every day she gets on the scale and she sees 2.2 kg more non stop. it increases every day). On 10-SEP-2021, the patient experienced whole body swollen. Laboratory data included: Weight (NR: not provided) 9 kg. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from gained 9kg (about 18 pounds. every day she gets on the scale and she sees 2.2 kg more non stop. it increases every day), and whole body swollen. This report was non-serious.
Pt received a second booster dose prior to recommended interval. Pt is not experiencing any adverse side effects. Pt feels fine as of today.
2/19 Engerix-B adult dose given at 8:50 a.m. PT reports approx 10:45 a.m. felt "shaking, nauseated, clammy and disoriented." She said she thought she was having a "hypoglycemic reaction" until about 1/2 hr later, she began itching "intensely", began wheezing, trouble swallowing and nasal congestion.
Severe diarrhea, profuse sweating, migraine, insomnia, C-diff, UTI, chills, swollen glands in neck, fluid in ears and extreme upper back pain, HBP (not normally an issue), high heart rate
A report was received from a health care professional on 5 November 2003 concerning a vaccine of unspecified demography who received expired Fluvirin on 1 October 2003.  On 1 October 2003 the vaccine received expired Fluvirin.  There was insufficient information to determine the reporter's causality assessment.  Update 1, 16 February 2004.  A follow-up report was received from a health care professional indicating that a 45 year old female vaccine received expired Fluvirin on 02 October 2003. No adverse event had occurred at the time of reporting.  No follow-up pending, all informaiton received.
Mild tenderness to site, mild headache and feeling tired for a week.  A week later my arm felt moderately sore and started feeling warm with red rashes, hives , accompanied by chills, achy feeling, no fever, like flu like feeling without fever and some headache. Red rashes stayed for a week. Topical cream applied(hydrocortisone, Triamcinolone acetonide ) and Benadryl tab taken, rashes gone after a week.
Brain fog, alterations in mood, dementia like problems identifying people and recall, fatigue, pain at injection site, fever
Itchy; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (Itchy) in an adult female patient who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Hidradenitis suppurativa.    No Medical History information was reported.   On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) Citrate Free, Solution for injection in pre-filled syringe. On an unknown date, the patient experienced PRURITUS (Itchy). At the time of the report, PRURITUS (Itchy) outcome was unknown.        The action taken with mRNA-1273 (Spikevax) (Intramuscular) was unknown.       No concomitant medication was reported. On an unknown date, the patient experienced ITCHY.  No treatment medication was reported. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.  Primary reporter declined to provide lot number information.   Causality for HUMIRA(ADALIMUMAB): The reporter's causality for the event(s) of ITCHY was not provided.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Child received Varicella vaccine. The vaccine had been stored at 8 deg for 24 or longer hours. Children to be revaccinated or titers drawn.
On 3/8/06 pt noticed 5 blisters at injection site. no itching but v painful (pain 6/10), mild fever started steroid cream 3/10 by 3/15 only 1 blister left scabbed over, feeling better, pain almost resolved, still moderately fatigued.
suspected vaccination failure/Every one who has gotten the shot has gotten the shingles; has gotten the shingles; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in an unspecified number of patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.  Additional details provided were as follows: The case was created for multiple patient. The reporter reported that everyone who had got the shot (that reporter knows) experienced Shingles. This case was considered as suspected vaccination failure since the details regarding completion of primary vaccination schedule, time to onset and laboratory test confirming shingles were unknown at the time of reporting. Follow-up would not be possible as no contact details available.
Pt recv vax on 3/19/99; on 3/21/99 pt exp urticarial rash; tx=Prelone, Atarax
frequent urination; discomfort; herpes; This spontaneous case was reported by a consumer and describes the occurrence of POLLAKIURIA (frequent urination), DISCOMFORT (discomfort) and HERPES VIRUS INFECTION (herpes) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced POLLAKIURIA (frequent urination), DISCOMFORT (discomfort) and HERPES VIRUS INFECTION (herpes). At the time of the report, POLLAKIURIA (frequent urination), DISCOMFORT (discomfort) and HERPES VIRUS INFECTION (herpes) outcome was unknown.            It was reported that patient previously received other doses of Moderna COVID-19 vaccine and recently prescribed an anti viral drug for herpes due to frequent urination and discomfort and she reported that she started experiencing these symptoms after vaccination and she thinks there is no connection but was not sure and also wants to get second booster of the Moderna COVID-19 vaccine. No concomitant medications were reported. Treatment medicine included anti- viral drug for herpes.
Started by pain in left shoulder and progressed to inability to move shoulder and arm without severe pain. Could not lift are to put on a jacket. Pain was progressively worse and did not start to regress for about a month and I still have pain in left shoulder to where it wakes me up at night if I roll to that side. This shot was administered to the Bursa and rotator cuff in my left shoulder.
It started with swelling in my cheek that quickly progressed to my lips and face. I went to the ER where it continued to progress to my hands. After the visit to the ER and a shot of epinephrine, DECADRON and VISTARIL, I felt better. I started taking hydroxyzine pamoate and methylprednisolone but by that evening, the condition worsened with welts starting in my hands, arms, then chest, back, head and legs. I went to an urgent care the next day and was given two more drugs to take - ZANTAC (hard to swallow) and Alkron H3 and was told that the reaction would run its course eventually. It started to get better in about 24 hours and then eventually, it went away. It was awful, something I had never experienced.
I received a second pneumonia vaccine shot on 10/25/2018. A year ago, I received PREVNAR 13 and had no side effects other than a sore arm. When I received PNEUMOVAX 23, within 9 hours, I could barely use my left arm. Within 11 hours, I had terrible chills and ached all over my body, including the arm from shoulder to wrist. Went to bed, had strong need to urinate in about 2 1/2 hours. That seem to relieve symptoms a bit so I drank water whenever I woke for rest of the night. Symptoms improved each time I urinated. I was less weak by morning and chills were gone.
This spontaneous report as received from a healthcare worker refers to a patient of unknown age and gender. On 25-JUN-2015, the patient was vaccinated with improperly stored dose of ROTATEQ oral, lot # K011947, expiration date 07-JUN-2016. No adverse events were reported. This is one of several reports received from the same source. Additional information has been requested.
dizziness; weak legs; sore arm; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (dizziness), PAIN IN EXTREMITY (sore arm) and MUSCULAR WEAKNESS (weak legs) in a 75-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Feb-2021, the patient experienced PAIN IN EXTREMITY (sore arm). On 06-Feb-2021, the patient experienced DIZZINESS (dizziness) and MUSCULAR WEAKNESS (weak legs). On 06-Feb-2021, PAIN IN EXTREMITY (sore arm) had resolved. At the time of the report, DIZZINESS (dizziness) and MUSCULAR WEAKNESS (weak legs) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       Most recent FOLLOW-UP information incorporated above includes: On 21-Apr-2021: NNI
This case was reported by a nurse via call center representative and described the occurrence of widespread rash in a 52-year-old female patient who received SHINGRIX (batch number HG4P3, expiry date 13th July 2020) for prophylaxis. On 23rd April 2018 10:00, the patient received the 1st dose of SHINGRIX (intramuscular) .5 ml. In April 2018, less than a week after receiving SHINGRIX, the patient experienced widespread rash. On an unknown date, the outcome of the widespread rash was recovered/resolved. It was unknown if the reporter considered the widespread rash to be related to SHINGRIX. Additional details were provided as follows: The patient received SHINGRIX on left deltoid. The patient developed a diffuse rash within 24 to 48 hours.
PATIENT STATES SHE WOKE UP IN THE MIDDLE OF THE NIGHT WITH A FEVER OF 101.5, BODY ACHES, AND FLU LIKE SYMPTOMS. TRIED TREATING FEVER WITH TYLENOL FOR PAIN AND FEVER. FELT RESTLESS FOR 2 DAYS.
chills, feverish, numbeness of left arm from elbow up to shoulder. Narrative:
Rash (L) arm several days - red large & hard with fever 102. BACTRIM.
2 mo old for well check. In semi-reclined position and oral rotavirus vaccine being administered into anterior 1/2 of mouth. Infant got pale, limp, apneic, sl. cyanotic. Improved with stimulation, but then recurred. Infant did cough once and spit up a small amt of clear fluid with some mixed in formula. Initial sats about 30-40 with HR in 80's. Infant stimulated with sats increased to 80's and increased heart rate. Infant grew blow by O2 with sats=100%. Infant transported via ambulance to local ER. In ER, CXR negative, infant observed. Sats 100% on RA, no further problems. Seen in follow up the next day, no problems overnight. Stable temps, feeding well, good color. CBC and electrolytes drawn. CBC and electrolytes WNL.
~ 2 hours after receiving vaccine patient reports vision changes/flashing lights for 1 hour, resolved on its own.  Felt warm and sweaty.  on day 2 - patient reports severe left arm pain and inability to move arm. days 4-5 cough and fatigue.
24hrs post vax pt's lt foot began to get a raised pinkish rash; temp 100-101ax, 8hrs later foot began to swell; Fever controlled w/APAP; swelling & rash gone by 3rd day;